Magnetic resonance imaging-derived parameters to predict response to regorafenib in recurrent glioblastoma.

Purpose: Regorafenib is a multikinase inhibitor, approved as a preferred regimen for recurrent glioblastoma (rGB). Although its effects on prolonging survival could seem modest, it is still unclear whether a subset of patients, potentially identifiable by imaging biomarkers, might experience a more...

Descripción completa

Detalles Bibliográficos
Publicado en:Neuroradiology Vol. 65; no. 10; pp. 1439 - 1446
Autores principales: Martucci, Matia, Ferranti, Andrea Maurizio, Schimperna, Francesco, Infante, Amato, Magnani, Francesca, Olivi, Alessandro, D'Alessandris, Quintino Giorgio, Gessi, Marco, Chiesa, Silvia, Mazzarella, Ciro, Russo, Rosellina, Giordano, Carolina, Gaudino, Simona
Formato: research tables/charts Journal Article
Publicado: Springer Nature Oct2023
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=171898840&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 171898840
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00283940
        NYZ
      jtl: Neuroradiology
      issn: 00283940
      maglogo: N
    pubinfo:
      dt: Oct2023
      vid: 65
      iid: 10
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        171898840
        163962469
        171898840
        171898840
        10.1007/s00234-023-03169-y
        171898840
      ppf: 1439
      ppct: 7
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Magnetic resonance imaging-derived parameters to predict response to regorafenib in recurrent glioblastoma.
      aug:
        au:
          Martucci, Matia
          Ferranti, Andrea Maurizio
          Schimperna, Francesco
          Infante, Amato
          Magnani, Francesca
          Olivi, Alessandro
          D'Alessandris, Quintino Giorgio
          Gessi, Marco
          Chiesa, Silvia
          Mazzarella, Ciro
          Russo, Rosellina
          Giordano, Carolina
          Gaudino, Simona
        affil: UOSD Neuroradiologia Diagnostica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy
      sug:
        subj:
          Glioma Drug Therapy
          Neoplasm Recurrence, Local Drug Therapy
          Glioma Prognosis
          Neoplasm Recurrence, Local Prognosis
          Tyrosine Kinase Inhibitors Therapeutic Use
          Antineoplastic Agents Therapeutic Use
          Tumor Markers, Biological Analysis
          Magnetic Resonance Imaging
          Neuroradiography
          Human
          Cancer Patients
          Cerebral Blood Volume
          Progression-Free Survival
          Overall Survival
          Survival Analysis
          Descriptive Statistics
          Comparative Studies
          Treatment Outcomes
      ab: Purpose: Regorafenib is a multikinase inhibitor, approved as a preferred regimen for recurrent glioblastoma (rGB). Although its effects on prolonging survival could seem modest, it is still unclear whether a subset of patients, potentially identifiable by imaging biomarkers, might experience a more substantial positive effect. Our aim was to evaluate the potential value of magnetic resonance imaging-derived parameters as non-invasive biomarkers to predict response to regorafenib in patients with rGB. Methods: 20 patients with rGB underwent conventional and advanced MRI at diagnosis (before surgery), at recurrence and at first follow-up (3 months) during regorafenib. Maximum relative cerebral blood volume (rCBVmax) value, intra-tumoral susceptibility signals (ITSS), apparent diffusion coefficient (ADC) values, and contrast-enhancing tumor volumes were tested for correlation with response to treatment, progression-free survival (PFS), and overall survival (OS). Response at first follow-up was assessed according to Response Assessment in Neuro-Oncology (RANO) criteria. Results: 8/20 patients showed stable disease at first follow-up. rCBVmax values of the primary glioblastoma (before surgery) significantly correlated to treatment response; specifically, patients with stable disease displayed higher rCBVmax compared to progressive disease (p = 0.04, 2-group t test). Moreover, patients with stable disease showed longer PFS (p = 0.02, 2-group t test) and OS (p = 0.04, 2-group t test). ITSS, ADC values, and contrast-enhancing tumor volumes showed no correlation with treatment response, PFS nor OS. Conclusion: Our results suggest that rCBVmax of the glioblastoma at diagnosis could serve as a non-invasive biomarker of treatment response to regorafenib in patients with rGB.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N